Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.